Health ❯ Healthcare ❯ Pharmaceuticals

Drug Development

Clinical Trials Obesity Treatments Monoclonal Antibodies Alzheimer's Disease Combination Therapy Eli Lilly Oncology Immunotherapy Novo Nordisk GLP-1 Drugs

Kodiak Drugs Clear Phase 3 for Wet AMD and Shares Soar

The company said it will seek U.S. approval by filing a Biologics License Application for Zenkuda in Q4 to pursue its first commercial product.

FDA Approves Juvmo as First D1/D5 Agonist for Parkinson’s Disease

Acadia’s Alzheimer’s Psychosis Drug Misses Mid‑Stage Goal

Amgen’s Dazodalibep Meets Primary Goal in Phase 3 Sjögren’s Trial

Iambic Therapeutics Files for Nasdaq IPO to Fund AI Cancer Pipeline

CHMP Recommends Expanding Enhertu Label to Add Adjuvant Use

Securities Suit Targets Capricor Over FDA Findings on Trial Analysis

Xenon Submits NDA for Epilepsy Drug as Psychiatric Trials Pause After Safety Signals

Gotistobart Extends Survival in Early PRESERVE‑003 Update

Amivantamab Plus Chemotherapy Shows Longest Survival for EGFR Exon 20 Insertion Lung Cancer

FDA Approves Isembyld, First Muscle‑Directed Therapy for Spinal Muscular Atrophy

B7‑H3 Antibody‑Drug Conjugates Cut Death Risk by Half in Relapsed Small‑Cell Lung Cancer

AstraZeneca’s Etcamah Falls Short in Pivotal SERENA‑4 Breast Cancer Trial

AI-Designed Drug Rentosertib Lowers Biological-Age Signals in Small Trial

AstraZeneca's Tozorakimab Cuts COPD Flare‑Ups in Two Phase 3 Trials

Novartis’ Del‑Desiran Misses Phase III and Triggers Large Share Selloff

FDA Approves Lisraya for Adult Dermatomyositis

FDA Clears Pancreatic Drug That Shows Early Promise in RAS‑Mutant Lung Cancer

Ultragenyx Phase 3 Angelman Drug Fails to Show Benefit

Lilly to Buy Merida Biosciences for Up to $2.875 Billion